Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Amicus Therapeutics
ClinicalTrials.gov Identifier:
NCT00925301
First received: June 19, 2009
Last updated: March 20, 2014
Last verified: March 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2014
  Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 25, 2013